Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- JANX
- Price
- 23.60
- Stock movement down
- -0.87 (-3.50%)
- Company name
- Janux Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.44B
- Ent value
- 1.45B
- Price/Sales
- 110.53
- Price/Book
- 2.20
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -44.73%
- 3 year return
- 21.26%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-09-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
JANX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 110.53 |
| Price to Book | 2.20 |
| EV to Sales | 111.46 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 60.09M |
| EPS (TTM) | -1.11 |
| FCF per share (TTM) | -0.69 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 13.05M |
| Gross profit (TTM) | 11.48M |
| Operating income (TTM) | -85.96M |
| Net income (TTM) | -60.54M |
| EPS (TTM) | -1.11 |
| EPS (1y forward) | -3.21 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 87.98% |
| Operating margin (TTM) | -658.76% |
| Profit margin (TTM) | -463.91% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 26.75M |
| Net receivables | 0.00 |
| Total current assets | 666.32M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 695.02M |
| Accounts payable | 2.46M |
| Short/Current long term debt | 23.43M |
| Total current liabilities | 17.17M |
| Total liabilities | 38.91M |
| Shareholder's equity | 656.10M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -36.99M |
| Capital expenditures (TTM) | 832.00K |
| Free cash flow (TTM) | -37.82M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -9.23% |
| Return on Assets | -8.71% |
| Return on Invested Capital | -9.20% |
| Cash Return on Invested Capital | -5.75% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 24.54 |
| Daily high | 24.62 |
| Daily low | 23.30 |
| Daily Volume | 833K |
| All-time high | 66.83 |
| 1y analyst estimate | 82.46 |
| Beta | 2.85 |
| EPS (TTM) | -1.11 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 11 Nov 2025 |
Downside potential
Loading...
Downside potential data
| JANX | S&P500 | |
| Current price drop from All-time high | -64.09% | -1.46% |
| Highest price drop | -83.14% | -56.47% |
| Date of highest drop | 9 Nov 2023 | 9 Mar 2009 |
| Avg drop from high | -48.13% | -10.99% |
| Avg time to new high | 44 days | 12 days |
| Max time to new high | 643 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.44B
Marketcap category
Small-cap
Description
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.
Employees
103
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page